Monday, August 26, 2019

Targeted DNA/RNA Sequencing Market Share, and Development Trends of Analysis Report 2025


27th August 2019 – Global Targeted DNA/RNA Sequencing Market is expected to reach USD 15.9 billion by 2025. Targeted sequencing is a technique in which a subgroup of genes or regions of the genome are isolated and sequenced. The technique enables researchers to analyze data, focus time, and expenses on target areas of interest and allows sequencing at advanced exposure levels. Targeted gene sequencing panels are important tools for analyzing precise mutations in a specified sample.

Next-generation sequencing (NGS) is a technique that plays important role in targeted sequencing and offers the resolution, scalability, and speed to assess targeted genes of interest. Multiple genes can be evaluated at a time by reducing cost and saving time. Moreover, targeted gene sequencing makes the study easier and produces smaller and manageable data set. The Targeted DNA/RNA Sequencing Market is estimated to grow at a significant CAGR over the future period as the scope and its applications are rising enormously across the globe.

Targeted DNA/RNA Sequencing Market is segmented based on method, types, applications, end users, and region. Amplicon generation and target enrichment are the two important methods used for Targeted DNA/RNA Sequencing that could be explored in forecast period.


AnRNA-based Targeted Sequencing and DNA-based Targeted Sequencing are the types of Targeted DNA/RNA Sequencing that could be explored in the foremost period. RNA-based Targeted Sequencing is a technique for sequencing and selecting specific pathways or transcripts of interest of gene expression microarray. The technique is used for measuring transcripts of interest for analyzing splice junction, differential expression, cSNPs, allele-specific expression, isoforms, and gene-fusions.

This method can be qualitative or quantitative. The market may be categorized based on applications like drug discovery, human biomedical research, plant & animal sciences, and others. Pharma & biotech entities, academic research, hospitals & clinics, and other end users could be explored in Targeted DNA/RNA Sequencing in the future period.

Globally, North America accounted for the largest market share of Targeted DNA/RNA Sequencing and is estimated to lead the overall market in the coming years. The reason behind the overall market growth could be permission from NIH to allow target-sequencing study in the region, existence of active governing bodies to assess the sequencing-based genetic tests, and presence of developed research and development sector with enhanced technology. The United States is a major consumer of Targeted DNA/RNA Sequencing in the coming years.

Instead, Europe and the Asia Pacific are also estimated to have a positive influence on the future growth. Europe is the second largest region with significant market share. However, Asia Pacific is estimated to grow at fastest pace with the highest CAGR in the foremost period. The aspects that may be ascribed to the growth comprise low price of NGS-based tests in China in comparison with the U.S., government initiative for developing NGS platform as regarded by regulatory agencies, and developing research and development sector. The developing countries like China, Japan, and India are the major consumers of Targeted DNA/RNA Sequencing in the region.

The key players of Targeted DNA/RNA Sequencing industry are Macrogen, Inc., Illumina, Inc., Genomatix GmbH, Hoffmann-La Roche Ltd., PierianDx, Agilent Technologies, Integrated DNA Technologies, Inc., Agilent Technologies, Bio-Rad Laboratories, GATC Biotech Ag, Pacific Biosciences of California, and Oxford Nanopore Technologies. These players are concentrating on inorganic growth to sustain themselves amongst fierce competition. As companies all over the world have to believe that alliance with a market would permit them proportional market existence and authority to declare the leadership position.

For More Details, Visit @ http://www.millioninsights.com

No comments:

Post a Comment